A meat allergy caused by ticks may be popping up in new parts of the U.S.
It's rare, but in some cases a tick bite can cause a person to develop an allergy to red meat.
Most cases, scientists believe, are linked to the lone star tick, a species typically found in the Southeastern U.S. and the lower Midwest.
Two case reports published this week, however, suggest that two other species — found elsewhere in the country — may also trigger the allergy.
When ticks bite, they release a steady stream of saliva that contains chemicals that keep their victim's blood flowing as they feed. Sometimes, the saliva contains a sugar molecule called alpha-gal. Alpha-gal syndrome, a reaction to the molecule that occurs in some people, causes a red meat allergy.
'Alpha-gal syndrome is relatively rare, but those who have it can have a full-on anaphylactic shock,' said Douglas Norris, a professor of molecular microbiology and immunology at the Johns Hopkins Bloomberg School of Public Health.
The Center for Disease Control and Prevention estimates nearly half a million people in the U.S. have alpha-gal syndrome.
'We do believe the lone star tick is still responsible for most of the cases of alpha-gal syndrome in the U.S.,' said Dr. Johanna Salzer, a veterinary medical officer and epidemiologist with the CDC's Division of Vector-Borne Diseases. Salzer worked on both of the new case reports, which were published Wednesday in the agency's journal, Emerging Infectious Diseases.
Those reports found cases of alpha-gal syndrome in Washington and Maine in two women who hadn't traveled to areas where the lone star tick typically lives.
Both women reported being bitten by ticks, which suggests that other species — including Ixodes scapularis, also called black-legged or deer ticks — may also be associated with alpha-gal syndrome, though much more rarely. A related tick, Ixodes pacificus, or the western black-legged tick, was also linked to the Washington case.
The CDC's map of suspected cases — which shows high concentrations in Alabama, Arkansas, Georgia, Mississippi, Missouri, Kansas, Kentucky, Oklahoma and Tennessee as well as Maryland, North Carolina and Virginia — 'would look very different if Ixodes scapularis was widely causing it,' Salzer said.
However, documented cases being associated with other ticks in the U.S. is 'certainly a big deal,' Matthew Aliota, an associate professor in the department of veterinary and biomedical sciences at the University of Minnesota.
Unlike Lyme disease or the Heartland virus, alpha-gal syndrome is not caused by a bacterium or virus. The syndrome is instead an immune reaction to alpha-gal, a sugar found in almost all nonprimate animals, including cows, horses and deer and which can be present in tick saliva.
For some people, being exposed to alpha-gal through a tick bite triggers an immunoglobulin E, or IgE, antibody response in the body. People who mount this response develop an allergy to meat that can take weeks to months to appear. Alpha-gal syndrome was discovered in 2009, and researchers are still working to answer a lot of questions about it — including why some people react to alpha-gal while many do not.
For most people who do develop alpha-gal syndrome, the allergic reaction occurs hours after they eat red meat.
'It's unique because it's a delayed reaction, roughly 2-8 hours, so you can have a hard time knowing the trigger,' Salzer said, noting that with other IgE allergies, such as peanuts or shellfish, the reaction is almost immediate.
Different people can also have different reactions, which can further complicate diagnosis.
In one case, a 61-year-old woman in Washington state went into anaphylactic shock 29 days after she remembers being bitten by a tick on her shoulder: After eating beef tacos, she broke out in hives and her tongue and throat swelled. It happened again after she ate pork.
In the other case, a 45-year-old woman in Maine had stomach pain and general malaise about 2 ½ hours after she ate roasted rabbit. About nine days earlier, she had removed a deer tick from her arm. After that first incident, she'd get sick a few hours after she ate any type of red meat. Beef elicited a bout of vomiting and diarrhea that eventually landed her in her doctor's office.
Both women tested positive for alpha-gal antibodies, and both recalled their bites being itchy and inflamed.
'Not everyone will have this local reaction, but it is pretty common,' Salzer said, referring to the itchy, inflamed bites. 'But there is a subset of people with alpha-gal syndrome who do not recall being bitten by ticks,' she said.
In 2023, the Maine CDC documented 23 cases of confirmed alpha-gal syndrome, but it's unclear how many may have encountered the ticks while traveling. (Lone star ticks are uncommon in Maine and Washington, but they have been found there.)
It's also possible that these other tick species in the U.S. have always been associated with alpha-gal, Norris said, but doctors haven't detected it nearly as often as with lone star ticks. Indeed, ticks in Africa, Australia, Central America and Europe and Central America are also known to trigger alpha-gal syndrome.
One thing is certain: Ticks, and the diseases they are associated with, are thriving.
'Tick populations in general, and particularly with lone star ticks, are exploding all over the United States,' Aliota said. 'Lone star ticks are moving into bigger geographic areas, and that range is continuing to expand with climate change.'
For this reason, it's important to take precautions to avoid tick bites. This includes using bug repellant and wearing long-sleeved shirts, pants and socks when outdoors during tick season, which typically begins in April. If you've been in wooded areas or tall grass, shower off and do a 'tick check' when you get home.
'The most important thing is preventing the tick bite altogether,' Salzer said.
This article was originally published on NBCNews.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Opinion - Beyond MAHA: Defeating obesity requires a new strategy
Obesity is a major health problem facing our country. According to the CDC, more than 40 percent of the U.S. population is obese, defined as having a body-mass index above 30. As astounding at that number is, it is perhaps even more surprising that nearly 20 percent of children in the U.S. are obese. Obesity leads to significant health challenges, including diabetes, stroke, cardiovascular disease and liver disease. It is clear that as a nation we must face this crisis on multiple fronts. Diet and exercise certainly help, and it's critical to ensure that people of all socioeconomic backgrounds have access to healthy foods (free of preservatives, unnecessary dyes, high fructose corn syrups etc.) and are educated in making healthy lifestyle choices. The MAHA or 'Make America Healthy Again' movement has highlighted this as one of its key objectives, and if it is successful, we should see an impact on obesity — especially in children, where diet and exercise have a huge impact on weight-related health outcomes. Obesity in adults, however, is often more challenging. Many adults with obesity struggle to lose weight, despite considerable efforts to modify their lifestyle through diet and exercise. This is because our metabolism changes as we age, and many adults who are overweight develop metabolic dysfunction or 'metabolic syndrome,' which then further perpetuates weight gain and exacerbates the situation. It has become clear in recent years that many people struggling with obesity require medical intervention – not just lifestyle intervention – and that prescriptions can substantially improve weight loss. The explosion in use of GLP-1 agonists, such as Wegovy and Zepbound, over the last two years has underscored the need for medical intervention in obese and overweight patients. Currently, about 6 percent of the U.S. population, or 15 million people, are on GLP-1 weight loss treatments, and the numbers are only expected to increase. However, while most patients lose 10 percent to 25 percent of their body weight while on a GLP-1, they do not maintain GLP-1 treatment in the long-term, with approximately 80 percent of patients discontinuing treatment within 1 year. Gastrointestinal side effects, injectable administration, and high cost have prevented long-term use of GLP-1's for weight maintenance. And unfortunately, most patients gain back all the weight after stopping the medication. Healthcare professionals and the pharmaceutical industry now recognize that obesity — like most other medical conditions — requires an 'arsenal' of treatments, rather than a one-size-fits-all approach. Post-GLP-1 weight maintenance is now widely recognized as an emerging unmet need. And patients who are not candidates for or cannot tolerate GLP-1s require alternatives. Diet and lifestyle modifications are important alongside prescription medications in fighting obesity. If we are going to be successful in overcoming this major health crisis, we need to ensure that both the pharmaceutical industry and groups like MAHA work hand in hand. Both treatment and prevention are critical in order to regain control of our nation's health. Dr. Shoshana Shendelman, Ph.D. is a scientist and entrepreneur who has founded numerous biotech companies. She is a pioneer in the development of drugs and therapeutics for rare and underserved diseases. Currently she is Vice Chair of the Advisory Board of Columbia University Medical Center and Columbia University Vagelos College of Physicians and Surgeons. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms
A new COVID variant known as NB.1.8.1 has made landfall in the United States. The variant, which was first detected in China this past January, currently accounts for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks ago. A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. To date, only 20 NB.1.8.1 sequences have been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.) It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2. 'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost. Here's what to know about the newest COVID variant that's gaining traction around the world. Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO). The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests. According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants. Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said. Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said. There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said. It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said. Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added. So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot. Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week. For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset. As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said. RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women Trump's FDA Has Axed COVID Boosters For Most People — And Medical Experts Are Deeply Worried New Trump Vaccine Policy Limits Access To COVID Shots


The Hill
2 hours ago
- The Hill
Beyond MAHA: Defeating obesity requires a new strategy
Obesity is a major health problem facing our country. According to the CDC, more than 40 percent of the U.S. population is obese, defined as having a body-mass index above 30. As astounding at that number is, it is perhaps even more surprising that nearly 20 percent of children in the U.S. are obese. Obesity leads to significant health challenges, including diabetes, stroke, cardiovascular disease and liver disease. It is clear that as a nation we must face this crisis on multiple fronts. Diet and exercise certainly help, and it's critical to ensure that people of all socioeconomic backgrounds have access to healthy foods (free of preservatives, unnecessary dyes, high fructose corn syrups etc.) and are educated in making healthy lifestyle choices. The MAHA or 'Make America Healthy Again' movement has highlighted this as one of its key objectives, and if it is successful, we should see an impact on obesity — especially in children, where diet and exercise have a huge impact on weight-related health outcomes. Obesity in adults, however, is often more challenging. Many adults with obesity struggle to lose weight, despite considerable efforts to modify their lifestyle through diet and exercise. This is because our metabolism changes as we age, and many adults who are overweight develop metabolic dysfunction or 'metabolic syndrome,' which then further perpetuates weight gain and exacerbates the situation. It has become clear in recent years that many people struggling with obesity require medical intervention – not just lifestyle intervention – and that prescriptions can substantially improve weight loss. The explosion in use of GLP-1 agonists, such as Wegovy and Zepbound, over the last two years has underscored the need for medical intervention in obese and overweight patients. Currently, about 6 percent of the U.S. population, or 15 million people, are on GLP-1 weight loss treatments, and the numbers are only expected to increase. However, while most patients lose 10 percent to 25 percent of their body weight while on a GLP-1, they do not maintain GLP-1 treatment in the long-term, with approximately 80 percent of patients discontinuing treatment within 1 year. Gastrointestinal side effects, injectable administration, and high cost have prevented long-term use of GLP-1's for weight maintenance. And unfortunately, most patients gain back all the weight after stopping the medication. Healthcare professionals and the pharmaceutical industry now recognize that obesity — like most other medical conditions — requires an 'arsenal' of treatments, rather than a one-size-fits-all approach. Post-GLP-1 weight maintenance is now widely recognized as an emerging unmet need. And patients who are not candidates for or cannot tolerate GLP-1s require alternatives. Diet and lifestyle modifications are important alongside prescription medications in fighting obesity. If we are going to be successful in overcoming this major health crisis, we need to ensure that both the pharmaceutical industry and groups like MAHA work hand in hand. Both treatment and prevention are critical in order to regain control of our nation's health. Dr. Shoshana Shendelman, Ph.D. is a scientist and entrepreneur who has founded numerous biotech companies. She is a pioneer in the development of drugs and therapeutics for rare and underserved diseases. Currently she is Vice Chair of the Advisory Board of Columbia University Medical Center and Columbia University Vagelos College of Physicians and Surgeons.